In re Metoprolol Succinate Direct Purchaser Antitrust Litigation, No. 06-52 (D. Del.)

In the Toprol case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of AstraZeneca’s branded drug Toprol XL (extended-release metoprolol succinate).  The case alleges that AstraZeneca fraudulently procured two patents and filed multiple baseless patent infringement lawsuits using those patents, solely in an effort to delay less-expensive generic competition, a violation of § 2 of the Sherman Act.  A $20 million settlement in the case has been approved by the court, and final judgment has been entered.